VERASTEM INC (VSTM) Stock Price, Quote, News and Overview
NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD
VSTM Quote, Performance and Key Statistics
7
+0.04 (+0.57%)
The current stock price of VSTM is 7 USD. In the past month the price increased by 14.94%. In the past year, price decreased by -39.5%.
VSTM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About VSTM
Company Profile
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
Company Info
VERASTEM INC
117 Kendrick Street, Suite 500
Cambridge MASSACHUSETTS 02494 US
CEO: Brian M. Stuglik
Employees: 73
Company Website: https://www.verastem.com/
Investor Relations: https://investor.verastem.com/events/
Phone: 17812924200
VERASTEM INC / VSTM FAQ
What is the stock price of VERASTEM INC today?
The current stock price of VSTM is 7 USD. The price increased by 0.57% in the last trading session.
What is the ticker symbol for VERASTEM INC stock?
The exchange symbol of VERASTEM INC is VSTM and it is listed on the Nasdaq exchange.
On which exchange is VSTM stock listed?
VSTM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERASTEM INC stock?
14 analysts have analysed VSTM and the average price target is 12.82 USD. This implies a price increase of 83.18% is expected in the next year compared to the current price of 7. Check the VERASTEM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERASTEM INC worth?
VERASTEM INC (VSTM) has a market capitalization of 311.57M USD. This makes VSTM a Small Cap stock.
How many employees does VERASTEM INC have?
VERASTEM INC (VSTM) currently has 73 employees.
What are the support and resistance levels for VERASTEM INC (VSTM) stock?
VERASTEM INC (VSTM) has a support level at 5.73 and a resistance level at 7.01. Check the full technical report for a detailed analysis of VSTM support and resistance levels.
Is VERASTEM INC (VSTM) expected to grow?
The Revenue of VERASTEM INC (VSTM) is expected to grow by 76% in the next year. Check the estimates tab for more information on the VSTM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERASTEM INC (VSTM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VSTM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VSTM, evaluating the profitability, health, valuation and growth aspects
- VERASTEM INC (VSTM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERASTEM INC (VSTM) Sales and EPS estimates to see what analysts future expectations are.
- VERASTEM INC (VSTM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERASTEM INC (VSTM) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERASTEM INC (VSTM) Stock Chart to make your own analysis
- VERASTEM INC (VSTM) Latest news and press-releases to stay up to date.
Does VERASTEM INC (VSTM) stock pay dividends?
VSTM does not pay a dividend.
When does VERASTEM INC (VSTM) report earnings?
VERASTEM INC (VSTM) will report earnings on 2025-03-12, after the market close.
What is the Price/Earnings (PE) ratio of VERASTEM INC (VSTM)?
VERASTEM INC (VSTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.19).
What is the Short Interest ratio of VERASTEM INC (VSTM) stock?
The outstanding short interest for VERASTEM INC (VSTM) is 14.27% of its float. Check the ownership tab for more information on the VSTM short interest.
VSTM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM is a bad performer in the overall market: 68.58% of all stocks are doing better.
VSTM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VSTM. VSTM may be in some trouble as it scores bad on both profitability and health.
VSTM Financial Highlights
Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS increased by 21.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -271.17% | ||
| Debt/Equity | 0.96 |
VSTM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to VSTM. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 26.17% and a revenue growth 76% for VSTM